Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Regeneron Pharmaceuticals, Inc., Sarepta Therapeutics or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Regeneron Pharmaceuticals, Inc., Sarepta Therapeutics and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Regeneron Pharmaceuticals, Inc., Sarepta Therapeutics and Inc.

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. Additionally, the company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. The company was incorporated in 1988 and is based in Tarrytown, New York.

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children’s Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Latest Biotechnology and Regeneron Pharmaceuticals, Inc., Sarepta Therapeutics, Inc. Stock News

As of September 2, 2026, Regeneron Pharmaceuticals, Inc. had a $85.1 billion market capitalization, compared to the Biotechnology median of $288.9 million. Regeneron Pharmaceuticals, Inc.’s stock is up 9.2% in 2026, up 4.3% in the previous five trading days and up 47.47% in the past year.

Currently, Regeneron Pharmaceuticals, Inc.’s price-earnings ratio is 21.1. Regeneron Pharmaceuticals, Inc.’s trailing 12-month revenue is $15.5 billion with a 27.9% net profit margin. Year-over-year quarterly sales growth most recently was 16.7%. Analysts expect adjusted earnings to reach $53.547 per share for the current fiscal year. Regeneron Pharmaceuticals, Inc. currently has a 0.4% dividend yield.

As of September 2, 2026, Sarepta Therapeutics, Inc. had a $2.5 billion market cap, putting it in the 56th percentile of all stocks. Sarepta Therapeutics, Inc.’s stock is up 5.9% in 2026, up 5.5% in the previous five trading days and up 27.81% in the past year.

Currently, Sarepta Therapeutics, Inc. does not have a price-earnings ratio. Sarepta Therapeutics, Inc.’s trailing 12-month revenue is $2.0 billion with a -6.9% net profit margin. Year-over-year quarterly sales growth most recently was -34.3%. Analysts expect adjusted earnings to reach $4.438 per share for the current fiscal year. Sarepta Therapeutics, Inc. does not currently pay a dividend.

How We Compare Regeneron Pharmaceuticals, Inc., Sarepta Therapeutics and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Regeneron Pharmaceuticals, Inc., Sarepta Therapeutics and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Regeneron Pharmaceuticals, Inc., Sarepta Therapeutics and Inc. Growth Grades

Company	Ticker	Growth
Regeneron Pharmaceuticals, Inc.	REGN	A
Sarepta Therapeutics, Inc.	SRPT	D

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Regeneron Pharmaceuticals, Inc. has a Growth Score of 82, which is Very Strong. Sarepta Therapeutics, Inc. has a Growth Score of 29, which is Weak.

The Growth Grade Winner: Regeneron Pharmaceuticals, Inc.

As you can clearly see from the Growth Grade breakdown above, Regeneron Pharmaceuticals, Inc. has a more attractive growth grade than Sarepta Therapeutics, Inc.. For investors who focus solely on how a company is growing relative to other companies in the same industry, Regeneron Pharmaceuticals, Inc. could be a good stock to add to their portfolio. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Regeneron Pharmaceuticals, Inc., Sarepta Therapeutics and Inc.’s Quality Grades

Company	Ticker	Quality
Regeneron Pharmaceuticals, Inc.	REGN	A
Sarepta Therapeutics, Inc.	SRPT	D

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Regeneron Pharmaceuticals, Inc. has a Quality Score of 81, which is Very Strong. Sarepta Therapeutics, Inc. has a Quality Score of 36, which is Weak.

The Quality Grade Winner: Regeneron Pharmaceuticals, Inc.

As you can clearly see from the Quality Grade breakdown above, Regeneron Pharmaceuticals, Inc. has a better overall quality grade than Sarepta Therapeutics, Inc.. For investors who are looking for companies with higher quality than others in the same industry, Regeneron Pharmaceuticals, Inc. could be a good stock to add to their portfolios. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Regeneron Pharmaceuticals, Inc., Sarepta Therapeutics and Inc.’s Momentum Grades

Company	Ticker	Momentum
Regeneron Pharmaceuticals, Inc.	REGN	A
Sarepta Therapeutics, Inc.	SRPT	A

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Regeneron Pharmaceuticals, Inc. has a Momentum Score of 87, which is Very Strong. Sarepta Therapeutics, Inc. has a Momentum Score of 81, which is Very Strong.

The Momentum Grade Winner: It’s a Tie!

Looking at the Momentum Grade breakdown above, both Regeneron Pharmaceuticals, Inc., Sarepta Therapeutics and Inc. have a grade of A. For those who focus solely on a company’s momentum, further research will need to be conducted into both companies to see if they fit your individual needs as an investor.

Other Regeneron Pharmaceuticals, Inc., Sarepta Therapeutics and Inc. Grades

In addition to Quality, Growth and Momentum, A+ Investor also provides grades for Value and Estimate Revisions.

Earnings estimate revisions scores take into account the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, surprises beget further surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Regeneron Pharmaceuticals, Inc., Sarepta Therapeutics and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Regeneron Pharmaceuticals, Inc., Sarepta Therapeutics or Inc. Stock?

Overall, Regeneron Pharmaceuticals, Inc. stock has a Growth Score of 82, Momentum Score of 87 and Quality Score of 81.

Sarepta Therapeutics, Inc. stock has a Growth Score of 29, Momentum Score of 81 and Quality Score of 36.

Comparing Regeneron Pharmaceuticals, Inc., Sarepta Therapeutics and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.